Accendra Health Cuts Guidance, Shares Plunge 34%

Accendra Health Inc (ACH) shares experienced a significant downturn, closing at $0.004855 on September 11, 2026, marking a 0.02% decline within the last 24 hours. The stock has faced substantial pressure over the past week, recording a 10.29% drop, while showing a marginal 0.48% increase over the past month. Year-to-date, the asset has contracted by 35.24%. This recent market performance follows the company’s release of second-quarter financial results and a revised outlook that has triggered a sharp reassessment of its near-term valuation.

Q2 Financial Performance and Audit Impacts

The company reported second-quarter adjusted EBITDA of $60.1 million, a figure that fell short of analyst expectations. The earnings per share (EPS) came in at -$0.19, compared to a forecast of $0.1204, resulting in a negative surprise of 257.81%. Revenue for the quarter was recorded at $613.2 million, slightly below the projected $632.21 million, representing a revenue surprise of -3.01%.

A primary driver behind the underperformance was the delay in collections stemming from intensified payer audits. These regulatory and administrative hurdles reduced both revenue and EBITDA by approximately $10 million during the quarter. Despite these headwinds, certain segments demonstrated resilience. Revenue from sleep-related services grew by 5.5% year-over-year, and diabetes care revenue increased by 4%. However, these gains were offset by continued weakness in respiratory, wound care, and continuous glucose monitoring (CGM) categories. When excluding the impact of payer delays, overall organic growth stood at a modest 2%.

Revised Guidance and Strategic Outlook

In response to the challenging operating environment, Accendra Health significantly lowered its full-year 2026 guidance. The company now projects revenue to fall within the range of $2.45 billion to $2.55 billion, down from previous estimates. Adjusted EBITDA guidance has also been reduced to a range of $300 million to $320 million. Following the announcement, shares plunged 34% to $1.86 in premarket trading, reflecting investor concern over the compressed margin profile and operational headwinds.

Management expressed confidence in a recovery trajectory, targeting a normalization of annual free cash flow to $100 million in 2027. This projection is contingent upon the successful launch of new partnerships and the stabilization of operational costs. The company anticipates that the fourth quarter will see a significant strengthening in performance as the effects of payer audits diminish and new revenue streams mature.

Leadership Transition and Balance Sheet Management

The company is also undergoing a leadership transition, with CEO Ed Pesicka planning to retire by the end of 2026. Despite the earnings miss, Accendra Health has taken steps to strengthen its balance sheet, reducing debt by $400 million since March. However, the firm continues to face cash flow pressure due to the aforementioned audit challenges.

Looking ahead, the company faces a critical period as it navigates the remainder of 2026. The upcoming November 4 earnings report will cover the period ending in September 2026, with analysts forecasting an EPS of $0.0379 and revenue of $624.76 million. Previous quarters have shown volatility, with the Q1 2026 results ending in March showing an EPS of -$0.04 against a forecast of -$0.101, and revenue of $627.8 million against a forecast of $646.24 million. The current guidance reduction highlights the uncertainty surrounding the company's ability to meet these future targets amid ongoing regulatory scrutiny and shifting payer dynamics.